Login to Your Account



$49M Series C Round

Immune Design Moving Cancer Immunotherapy Platform into Clinic

By Jennifer Boggs
Managing Editor

Wednesday, October 30, 2013
financings_resized.jpg

As further proof that cancer immunotherapy is no longer the biopharma pariah of several years ago, Immune Design Corp. closed a $49 million Series C round to advance its lead candidates into the clinic.

The financing, which nearly doubles the Seattle-based biotech’s $52 million venture capital to date, includes $32.5 million up front, with the remaining $16.5 million anticipated after the firm gathers Phase I data, said President and CEO Carlos Paya. Immune Design aims to move into the clinic next year.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription